Authors: Dumontet, C Morschhauser, F Solal-Celigny, P Bouafia, F Bourgeois, E Thieblemont, C Leleu, X Hequet, O Salles, G Coiffier, B

Citation: C. Dumontet et al., Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma, BR J HAEM, 113(3), 2001, pp. 772-778

Authors: Morschhauser, F Cayuela, JM Martini, S Baruchel, A Rousselot, P Socie, G Berthou, P Jouet, JP Straetmans, N Sigaux, F Fenaux, P Preudhomme, C

Citation: F. Morschhauser et al., Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: A multicenter study of 51 patients, J CL ONCOL, 18(4), 2000, pp. 788-794

Authors: Brice, P Divine, M Simon, D Coiffier, B Leblond, V Simon, M Voilat, L Devidas, A Morschhauser, F Rohrlich, P Andre, M Lepage, E Ferme, C

Citation: P. Brice et al., Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD), ANN ONCOL, 10(12), 1999, pp. 1485-1488

Authors: Leclercq, I Mortreux, F Morschhauser, F Duthilleul, P Desgranges, C Gessain, A Cavrois, M Vernant, JP Hermine, O Wattel, E

Citation: I. Leclercq et al., Semiquantitative analysis of residual disease in patients treated for adult T-cell leukaemia lymphoma (ATLL), BR J HAEM, 105(3), 1999, pp. 743-751